Japan's health committee is expected to vote today on an amendment to the Health Insurance Law that increases costs for specific medications [1].
The measure seeks to reduce the social-insurance premium burden on the working generation while expanding support for families and long-term patients.
Under the proposed changes, patients would face a 25% [1] additional co-payment for drugs that are similar to over-the-counter options, such as Loxonin and Allegra. This shift aims to discourage the use of prescription-only channels for medications readily available as OTC products.
In addition to the new drug costs, the amendment introduces free childbirth costs to support new parents. The legislation also includes revisions to the ceiling of the high-cost medical expense system to mitigate the financial impact on patients requiring long-term care [1], [2].
Reports regarding the legislative process vary. Some sources said the amendment was approved by the Health, Labour and Welfare Committee of the House of Councillors [1], while others said the approval was by the committee of the House of Representatives [2].
Conflicting reports also exist regarding the timing of the committee vote. While some data suggests the vote occurred on April 24 [4], other reports said the committee vote is scheduled for May 28, 2026 [1].
If the committee approves the measure today, a full vote in the Diet is scheduled for May 29, 2026 [1].
“Patients would face a 25% additional co-payment for drugs that are similar to over-the-counter options.”
This legislative shift reflects Japan's struggle to balance a shrinking workforce with an aging population. By increasing the cost of 'OTC-like' prescriptions, the government is attempting to lower the systemic cost of healthcare and shift low-risk medication consumption toward the private market. Simultaneously, the introduction of free childbirth costs is a strategic effort to combat the country's declining birth rate by reducing the immediate financial barriers to starting a family.
